Literature DB >> 20167576

Ketogenic diet slows down mitochondrial myopathy progression in mice.

Sofia Ahola-Erkkilä1, Christopher J Carroll, Katja Peltola-Mjösund, Valtteri Tulkki, Ismo Mattila, Tuulikki Seppänen-Laakso, Matej Oresic, Henna Tyynismaa, Anu Suomalainen.   

Abstract

Mitochondrial dysfunction is a major cause of neurodegenerative and neuromuscular diseases of adult age and of multisystem disorders of childhood. However, no effective treatment exists for these progressive disorders. Cell culture studies suggested that ketogenic diet (KD), with low glucose and high fat content, could select against cells or mitochondria with mutant mitochondrial DNA (mtDNA), but proper patient trials are still lacking. We studied here the transgenic Deletor mouse, a disease model for progressive late-onset mitochondrial myopathy, accumulating mtDNA deletions during aging and manifesting subtle progressive respiratory chain (RC) deficiency. We found that these mice have widespread lipidomic and metabolite changes, including abnormal plasma phospholipid and free amino acid levels and ketone body production. We treated these mice with pre-symptomatic long-term and post-symptomatic shorter term KD. The effects of the diet for disease progression were followed by morphological, metabolomic and lipidomic tools. We show here that the diet decreased the amount of cytochrome c oxidase negative muscle fibers, a key feature in mitochondrial RC deficiencies, and prevented completely the formation of the mitochondrial ultrastructural abnormalities in the muscle. Furthermore, most of the metabolic and lipidomic changes were cured by the diet to wild-type levels. The diet did not, however, significantly affect the mtDNA quality or quantity, but rather induced mitochondrial biogenesis and restored liver lipid levels. Our results show that mitochondrial myopathy induces widespread metabolic changes, and that KD can slow down progression of the disease in mice. These results suggest that KD may be useful for mitochondrial late-onset myopathies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20167576     DOI: 10.1093/hmg/ddq076

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  74 in total

1.  Metabolically induced heteroplasmy shifting and l-arginine treatment reduce the energetic defect in a neuronal-like model of MELAS.

Authors:  Valerie Desquiret-Dumas; Naig Gueguen; Magalie Barth; Arnaud Chevrollier; Saege Hancock; Douglas C Wallace; Patrizia Amati-Bonneau; Daniel Henrion; Dominique Bonneau; Pascal Reynier; Vincent Procaccio
Journal:  Biochim Biophys Acta       Date:  2012-01-28

Review 2.  Maternally inherited mitochondrial respiratory disorders: from pathogenetic principles to therapeutic implications.

Authors:  Martine Uittenbogaard; Anne Chiaramello
Journal:  Mol Genet Metab       Date:  2020-06-27       Impact factor: 4.797

Review 3.  Mitochondria: in sickness and in health.

Authors:  Jodi Nunnari; Anu Suomalainen
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

Review 4.  Mitochondrial Diseases Part III: Therapeutic interventions in mouse models of OXPHOS deficiencies.

Authors:  Susana Peralta; Alessandra Torraco; Luisa Iommarini; Francisca Diaz
Journal:  Mitochondrion       Date:  2015-01-29       Impact factor: 4.160

Review 5.  Therapeutic Approaches to Treat Mitochondrial Diseases: "One-Size-Fits-All" and "Precision Medicine" Strategies.

Authors:  Emanuela Bottani; Costanza Lamperti; Alessandro Prigione; Valeria Tiranti; Nicola Persico; Dario Brunetti
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

Review 6.  Neurodevelopmental manifestations of mitochondrial disease.

Authors:  Marni J Falk
Journal:  J Dev Behav Pediatr       Date:  2010-09       Impact factor: 2.225

Review 7.  The mitochondrial paradigm for cardiovascular disease susceptibility and cellular function: a complementary concept to Mendelian genetics.

Authors:  David M Krzywanski; Douglas R Moellering; Jessica L Fetterman; Kimberly J Dunham-Snary; Melissa J Sammy; Scott W Ballinger
Journal:  Lab Invest       Date:  2011-06-06       Impact factor: 5.662

Review 8.  Ketogenic diets in patients with inherited metabolic disorders.

Authors:  S Scholl-Bürgi; A Höller; K Pichler; M Michel; E Haberlandt; D Karall
Journal:  J Inherit Metab Dis       Date:  2015-06-25       Impact factor: 4.982

Review 9.  Multifaceted role of insulin-like growth factors and mammalian target of rapamycin in skeletal muscle.

Authors:  Robert A Frost; Charles H Lang
Journal:  Endocrinol Metab Clin North Am       Date:  2012-05-10       Impact factor: 4.741

Review 10.  Mitochondrial Diseases Part II: Mouse models of OXPHOS deficiencies caused by defects in regulatory factors and other components required for mitochondrial function.

Authors:  Luisa Iommarini; Susana Peralta; Alessandra Torraco; Francisca Diaz
Journal:  Mitochondrion       Date:  2015-01-29       Impact factor: 4.160

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.